Drug Price Trends for XCOPRI

Average Pharmacy Cost for XCOPRI

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
XCOPRI 150 MG TABLET	71699-0150-30	39.93925	EACH	2026-01-01
XCOPRI 50-100 MG TITRATION PAK	71699-0202-28	42.71469	EACH	2026-01-01
XCOPRI 100 MG TABLET	71699-0100-30	39.93082	EACH	2026-01-01
XCOPRI 200 MG TABLET	71699-0200-30	39.94141	EACH	2026-01-01
XCOPRI 150-200 MG TITRATION PK	71699-0203-28	42.64112	EACH	2026-01-01

Market Analysis and Price Projections for XCOPRI (cenobamate)

Last updated: February 19, 2026

What is XCOPRI and Its Market Position?

XCOPRI (cenobamate) is an anti-seizure medication approved by the FDA in May 2019 for adjunctive treatment of partial-onset seizures in adults. Developed by SK Biopharmaceuticals, it entered a competitive epilepsy treatment market encompassing drugs such as lamotrigine, levetiracetam, and carbamazepine.

Market Size and Growth Drivers

Epilepsy Market Overview

• The global epilepsy market was valued at approximately USD 6.4 billion in 2022.
• Expected CAGR: 4.8% from 2023 to 2030.
• Growth drivers include increased diagnosis rates, expanding indications, and new therapeutic options.

Seizure Treatment Segment

• Subset of the larger epilepsy market; represents roughly 35-40% of total epilepsy treatments.
• Partial-onset seizures account for approximately 60% of epilepsy cases.
• There are an estimated 50 million epilepsy patients worldwide, with ~30 million experiencing partial seizures.

XCOPRI’s Market Penetration

• Launched in the U.S. with a targeted indication.
• Initial sales projected at USD 200 million in 2022.
• Market penetration remains in early stages, with expansion dependent on clinical positioning and formulary access.

Competitive Landscape

Drug Name	Class	Market Share (2022)	Key Differentiators
Levetiracetam (Keppra)	Broad-spectrum AED	25%	Well-established, broad label
Lamotrigine (Lamictal)	Broad-spectrum AED	20%	Favorable for comorbid depression
Carbamazepine	Older AED	15%	Cost-effective, widely used
Lacosamide	Partial-onset AED	10%	Fewer drug interactions
XCOPRI	Partial-onset AED	3% (2022)	Uniques mechanism, new option

Limited by its recent market entry and unique mechanism, XCOPRI's adoption hinges on efficacy, safety profile, and regulatory status across markets.

Pricing Strategy and Projections

Current Pricing in the U.S.

• Average Wholesale Price (AWP): USD 600–700 per 30-day supply.
• Estimated Medicaid/Biosimilar discounts reduce net prices to approximately USD 500.

Cost Comparison

Drug	30-Day Supply Price	Class	Comments
XCOPRI	USD 600–700	Novel AED	High efficacy in refractory cases, early access bias
Levetiracetam	USD 120–150	Broad-spectrum AED	Cost-effective, high market shares
Lamotrigine	USD 80–120	Broad-spectrum AED	Widely prescribed, lower price point

Price Projections (2023–2027)

• 2023: USD 600–700 initial, expected to stabilize with discounts.
• 2024–2025: Slight decrease to USD 550–600 as market expands and generics potentially enter.
• 2026–2027: Prices may decline further to USD 450–550 with increased competition and potential market saturation.

Factors Affecting Price Trends

• Patent expiry looming (currently patent-protected until approximately 2030 in the U.S.).
• Entry of biosimilars or generics could halve prices.
• Expanded labeling to additional seizure types or populations could increase volume, offsetting slight price declines.
• Payer negotiations and formulary placement influence net prices.

Regulatory and Patent Considerations

• Patent Status: Patents expire around 2030 in the U.S., with potential for patent challenges or extensions based on formulation or delivery method.
• Market Approvals: Pending approvals in Europe, Japan, and other markets may drive volume expansion.

Revenue and Growth Estimates

Year	Estimated U.S. Revenue	Assumed Market Share	Market Penetration	Comments
2023	USD 200 million	3%	Early adoption	Launch phase, prescriber familiarity building
2024	USD 300 million	4–5%	Growing acceptance	Additional formulary placements, expanding indications
2025	USD 400 million	6%	Increasing market	Post-patent expiry competition, price stabilization
2026+	USD 500+ million	8+%	Mature market	Saturation, global expansion

Key Takeaways

• XCOPRI has a niche within the partial-onset seizure market, with limited current market share.
• Pricing is initially high, with potential reductions as competition and patent expiry approach.
• Growth relies on expanding indications, regulatory approvals outside the U.S., and clinical efficacy positioning.
• The overall epilepsy market will influence XCOPRI’s revenue potential, with a CAGR of about 4.8% projected until 2030.

FAQs

1. What factors could lower XCOPRI’s price in the future?
Introduction of generics, increased competition, patent expiry, and formulary negotiations could push prices below USD 450 per 30-day supply.

2. How does XCOPRI compare to other seizure drugs in pricing?
It is priced higher than older AEDs like lamotrigine or levetiracetam but remains competitive relative to newer or specialty formulations.

3. What are the key growth opportunities for XCOPRI outside the U.S.?
European approval, expansion into Asian markets, and additional indications could significantly expand volume.

4. How might patent expiry impact XCOPRI’s revenue?
Patent expiry around 2030 may allow biosimilar entry, causing price reductions and volume increases, potentially impacting revenue margins.

5. What is the projected timeline for XCOPRI’s market share increase?
It is expected to reach a 6–8% share in the partial-onset seizure market by 2026, depending on clinical positioning, insurance access, and competition.

---

References

[1] Grand View Research. (2022). Epilepsy Market Size, Share & Trends Analysis.
[2] IQVIA. (2022). U.S. Prescription Drug Market Analysis.
[3] FDA. (2019). XCOPRI (cenobamate) approval announcement.
[4] EvaluatePharma. (2023). Global Oncology and Neurology Market Forecasts.
[5] SK Biopharmaceuticals. (2021). XCOPRI Product Monograph.